Objectives
  • To be able to perform specialist assessment, treatment and counselling of patients with various types of neuroendocrine neoplasms (NENs)

Awareness
  • Awareness of the existence of different biological and pathological subtypes, NENs with various clinical presentations and prognoses

  • Recognition of the availability of different diagnostic procedures, including histopathology, biomarkers, molecular imaging, radiology and endoscopies

  • Awareness of the WHO 2010 Classification System and the European Neuroendocrine Tumour Society (ENETS) TNM Staging System for NENs

  • Awareness of the existence of different prognostic factors

  • Appreciation of the importance of the multimodality approach to the treatment of NENs

Knowledge
  • Familiarity with the indications for different diagnostic tools such as histopathology, biomarkers, molecular imaging, radiology and endoscopies

  • Knowledge of the implications of the different pathological and biological subtypes of NENs (functioning vs non-functioning tumours) with regard to primary tumour localisation for the selection of appropriate treatment strategies

  • Familiarity with inherited forms of NENs (multiple neuroendocrine neoplasia MEN-1, MEN-2, Von Hippel-Lindau, tuberous sclerosis)

  • Familiarity with the risk assessment work-up of prognostic factors, especially the grading and staging system for NENs

  • Familiarity with the indications and value of surgery, radiation therapy, chemotherapy, hormonal agents, biological agents and targeted agents

  • Familiarity with the role of somatostatin analogues for antitumour control and symptom control

  • Understanding of the role of chemotherapy versus targeted therapy in the treatment of pancreatic NENs

  • Understanding of the role of peptide receptor radiotherapy (PRRT) in relation to other treatment modalities for NENs

  • Understanding of the side effects developing during the different therapies for NENs

  • Familiarity with hormone-related emergencies during treatment of NENs

Skills
  • Ability to contribute actively to the management of various subtypes of NENs

  • Ability to discuss critically the treatment options/recommendations

  • Ability to perform a history and physical examination in NEN patients, including different subtypes

  • Ability to contribute to discussions on general management strategies in the multidisciplinary team and tumour board

  • Ability to prescribe various therapies, including cytotoxic agents as well as targeted agents

  • Ability to correctly allocate patients with NENs to PRRT

  • Ability to determine therapy according to the WHO Grading System as well as ENETS TNM Staging System and primary tumour localisation

  • Ability to manage side effects of various chemotherapeutic, hormonal agents, biological agents and targeted agents as well as PRRT

  • Ability to determine the indications for local–regional treatment of liver metastases with embolisation/radioembolisation